| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Arthritis Therapeutics to 2016
Arthritis Therapeutics to 2016 
High Growth Rate and Increasing Use of Biologics Has Made Arthritis Therapeutics Market Attractive
Hyderabad,
AP,
India
(prbd.net)
14/10/2010
"Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
"
The global arthritis therapeutics market is a fast growing market, with arthritis considered to be the prime factor for chronic disability in the workforce .In 2009, the global arthritis therapeutics market was worth $18.4 billion, which is forecast to grow to $30 billion by 2016, showing a growth rate of 7.3% between 2009 and 2016. The arthritis therapeutics market has been growing at a fast pace over the past few years, and is expected to accelerate in the coming years. However, the market will face a marginal decline in revenues due to the patent expiries of the biggest selling drugs, including Celebrex (celecoxib) and Humira (adalimumab), between 2009 and 2016. However, the launch of blockbuster drugs such as Vicodin and Simponi along with the presence of many potential biologics in late stage development will offset the decline in revenues. In addition, the increase in the incidence rates of osteoarthritis, rheumatoid arthritis and psoriatic arthritis will trigger growth in the global arthritis therapeutics market. As a result, the market will continue to remain fast growing, thereby attracting the activities of major pharmaceutical companies.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Arthritis-Therapeutics-Market-to-2016-Biologics-Revolutionize-Treatment-of-Rheumatoid-Arthritis-RA-and-Psoriatic-Arthritis-PsA&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
The arthritis therapeutics market has a strong pipeline base that will support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are active in their pipeline for arthritis. One of the major activities is the development of biologics as a part of new treatment options. There are also some disease modifiers in the pipeline related to osteoarthritis that are expected to enter the market in 2018. The entry of these disease modifiers will boost the osteoarthritis therapeutics market, thereby bringing about further rises in the arthritis therapeutics market in the coming years. The rapid entry of new players and the highly active pipeline will intensify competition.
GBI Research, the leading business intelligence provider has released its latest research “Arthritis Therapeutics to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis”, which essentially provides insights on arthritis therapeutics sales and price forecasts until 2016. The report also examines the global arthritis therapies treatment usage patterns. In addition, the geographical distribution of arthritis therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the arthritis Research and Development (R&D) pipeline and the potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three arthritis therapeutic indications, which are osteoarthritis, rheumatoid arthritis and psoriatic arthritis. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving arthritis therapies is also presented.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Arthritis-Therapeutics-Market-to-2016-Biologics-Revolutionize-Treatment-of-Rheumatoid-Arthritis-RA-and-Psoriatic-Arthritis-PsA&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|